Drug Trial Radar · NCT06075537
An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
99
Planned (sponsor's estimate)
Start
Sep 20, 2023
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- Denali Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multiregional open-label extension (OLE) to assess the safety, tolerability, and efficacy of long-term treatment with tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant intravenous (IV) enzyme replacement therapy (ERT) for Hunter syndrome (MPS II). Participants who complete at least through the Week 49 visit in Study DNLI-E-0002 and do not discontinue study intervention early and participants who complete Study DNLI-E-0007 will be enrolled in this OLE. All participants will receive DNL310 for up to 5 years from the time of entry in this OLE. Participants, site staff, and the Sponsor will remain blinded to the original treatment assignment for participants entering this OLE from Study DNLI-E-0007.
Conditions
- Mucopolysaccharidosis II
Interventions
tividenofusp alfaDrug
Intravenous repeating dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and intensity of treatment-emergent adverse events (TEAEs)Time frame: 5 years
- Clinically significant changes in urine total glycosaminoglycan (GAG) concentrations throughout the treatment periodTime frame: 5 years
- Incidence and intensity of infusion-related reactions (IRRs)Time frame: 5 years
Locations
32 sites in 14 countries. Site status is shown where the registry gives one.
UCSF Benioff Children's Hospital Oakland
Oakland, California
Ann and Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois
Hackensack University Medical Center
Hackensack, New Jersey
UNC Children's Research Institute
Chapel Hill, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
The University of Texas Medical School at Houston
Houston, Texas
Huntsman Cancer Hospital
Salt Lake City, Utah
Sanatorio Mater Dei
Buenos Aires, Argentina
UZ Brussel
Jette, Belgium
Universitair Ziekenhuis Antwerpen
Edegem, Antwerpen, Belgium
Hospital Clinicas Porto Alegre
Porto Alegre, Brazil
University of Alberta - Faculty of Medicine & Dentistry
Edmonton, Alberta, Canada
Hospital for Sick Children
Toronto, Ontario, Canada
McGill University Health Center
Montreal, Quebec, Canada
Vseobecna Fakultni Nemocnice V Praze
Prague, Czechia
Hopital Jeanne De Flandre - Metabolic Diseases Unit
Lille, France
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
SpinCS GmbH
Höchheim, Germany
ASST di Cremona
Cremona, Italy
Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia
Udine, Italy
Erasmus Medical Center - Sophia Children's Hospital
Rotterdam, Netherlands
Hospit U. Vall d'Hebron - PPDS
Barcelona, Spain
Hospital Infantil Universitario Niño Jesús
Madrid, Spain
Drottning Silvias Barn Och Ungdomssjukhus
Gothenburg, Sweden
University Medical Faculty Balcali Hospital
Adana, Turkey (Türkiye)
Gazi Universitesi Tip Fakultes
Ankara, Turkey (Türkiye)
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
Royal Free Hospital
London, United Kingdom
Great Ormond Street Hospital
London, United Kingdom
Royal Manchester Children's Hospital
Manchester, United Kingdom
Salford Royal Hospital
Salford, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.